SpyGlass Pharma Appoints Shannon Treviño as General Counsel Ahead of BIM-IOL Phase 3 Completion

With two registrational Phase 3 trials enrolling and an NDA submission on the horizon, SpyGlass Pharma has brought in Shannon Treviño as General Counsel — a hire that signals the company is structuring its legal and compliance infrastructure for the regulatory workload ahead.

Treviño joins from Inari Medical, where she served as General Counsel and Corporate Secretary and guided the company through its $4.9 billion acquisition by Stryker, as well as Inari's acquisition and integration of LimFlow. Her background spans corporate, M&A, and securities law across healthcare, with earlier experience at Latham & Watkins and Sugg Law Group advising growth-stage companies on governance, capital formation, and commercial contracts.

For regulatory and QA leads tracking the BIM-IOL pipeline, the context is relevant: SpyGlass Pharma's lead candidate, the Bimatoprost Drug Pad-IOL System, is a non-bioerodible sustained-release device designed for implantation during routine cataract surgery, targeting intraocular pressure reduction in patients with open-angle glaucoma or ocular hypertension. The system is engineered to deliver bimatoprost — an FDA-approved prostaglandin analog — continuously over three years. Because the product combines a drug with an implantable device, the eventual submission pathway will carry both NDA and PMA considerations, with corresponding manufacturing, sterility assurance, and process validation requirements that will need to be in place well before any approval filing.

SpyGlass Pharma has indicated it plans to work with the FDA through Phase 3 completion before submitting for approval. Treviño holds a J.D. summa cum laude from LMU Loyola Law School and an A.B. from Princeton University; she also spent eight years as a Clinical Professor at Loyola Marymount University's Law School, where she co-authored two editions of a textbook on startup financing.

The pace at which SpyGlass Pharma advances toward an NDA or combination-product submission will be a measurable indicator of how effectively this expanded leadership team translates Phase 3 data into a regulatory package.

Source: SpyGlass Pharma, Inc. via GlobeNewswire, June 15, 2026.